Objective: Previous studies suggested that endothelin-l (ET-1) may play a pathophysiological role in myocardial ischemia/reperfusion injury. This study was designed to investigate the effects of the selective ET-A receptor antagonist BQ123 and the selective ET-B receptor antagonist BQ788 on myocardial and endothelial function after reversible deep hypothermic ischemia in a heterotopic rat heart transplantation model. Methods: Isogenic intraabdominal heterotopic transplantation was performed in Lewis rats. After 1 h of cold ischemic preservation reperfusion was started either after application of placebo (control), BQ123 (3 mu mol/kg/min), BQ788 (3 mu mol/kg/min), ET-1 (8 pmol/kg/min) or simultaneous infusion of BQ123 or B4788 and ET-1, respectively (n=12 each). An implanted balloon was used to obtain pressure-volume relations of the transplanted heart. Myocardial blood flow (MBF) was assessed by the hydrogen-clearance method. Measurements were taken after 1 and 24 h of reperfusion. Endothelium-dependent vasodilation to acetylcholine (ACH) and endothelium-independent vasodilation to sodium nitroprusside were also determined. Results: Both BQ123 and B4788 significantly improved myocardial and endothelial functional recovery during early reperfusion, whereas ET-I significantly impaired myocardial and endothelial function. Simultaneous infusion of ET-I diminished the effects of BQ123 and BQ788. Although myocardial function and baseline MBF were similar in all groups after 24 h of reperfusion, endothelium dependent vasodilation to ACH was still significantly higher in the BQ123 and BQ788 groups and lower in the ET-I groups (p<0.05). Conclusions: These results suggest that endogenous ET release is involved in the pathogenesis of reperfusion injury after heart transplantation. ET-A and ET-B receptor antagonists may be useful to reduce ischemia/reperfusion injury. (C) 1998 Elsevier Science B.V. All rights reserved.
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND
DAGASSAN, PH
;
BREU, V
论文数: 0引用数: 0
h-index: 0
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND
BREU, V
;
CLOZEL, M
论文数: 0引用数: 0
h-index: 0
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND
CLOZEL, M
;
CLOZEL, JP
论文数: 0引用数: 0
h-index: 0
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND
DAGASSAN, PH
;
BREU, V
论文数: 0引用数: 0
h-index: 0
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND
BREU, V
;
CLOZEL, M
论文数: 0引用数: 0
h-index: 0
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND
CLOZEL, M
;
CLOZEL, JP
论文数: 0引用数: 0
h-index: 0
机构:
F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLANDF HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, DIV PHARMA, CH-4002 BASEL, SWITZERLAND